IRIS
CARACCIOLO, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.090
AS - Asia 764
EU - Europa 685
SA - Sud America 185
AF - Africa 16
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 3
Totale 2.750
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.054
IT - Italia 396
SG - Singapore 379
CN - Cina 187
BR - Brasile 149
DE - Germania 98
IN - India 88
GB - Regno Unito 67
VN - Vietnam 39
SE - Svezia 35
FI - Finlandia 33
CA - Canada 25
HK - Hong Kong 25
NL - Olanda 13
FR - Francia 10
AR - Argentina 9
EC - Ecuador 9
ID - Indonesia 9
ZA - Sudafrica 9
JP - Giappone 8
BD - Bangladesh 7
EU - Europa 7
MX - Messico 7
RU - Federazione Russa 7
AT - Austria 6
ES - Italia 5
VE - Venezuela 5
CL - Cile 4
CO - Colombia 4
AU - Australia 3
CZ - Repubblica Ceca 3
EG - Egitto 3
IQ - Iraq 3
PK - Pakistan 3
PY - Paraguay 3
TR - Turchia 3
UA - Ucraina 3
CH - Svizzera 2
ET - Etiopia 2
IR - Iran 2
KE - Kenya 2
LB - Libano 2
LT - Lituania 2
PE - Perù 2
PL - Polonia 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
EE - Estonia 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
JM - Giamaica 1
MY - Malesia 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
RO - Romania 1
SA - Arabia Saudita 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
Totale 2.750
Salva come PNG Salva come JPEG
Città #
Singapore 191
Chandler 152
Dallas 78
Munich 71
Santa Clara 69
Bengaluru 66
Hefei 66
Ashburn 63
Chicago 50
London 47
Catanzaro 44
Lawrence 44
Princeton 44
Milan 43
Beijing 42
Naples 25
Hong Kong 22
Turku 22
Wilmington 18
Los Angeles 17
Ho Chi Minh City 15
Rome 15
São Paulo 15
New York 14
Des Moines 13
Ottawa 13
Carbonia 12
Parma 12
Brooklyn 11
Helsinki 11
Hanoi 10
Boardman 9
Cosenza 8
Ercolano 8
Redwood City 8
San Nicola Manfredi 8
Santo Stefano di Rogliano 8
Afragola 7
Boston 6
Melito di Porto Salvo 6
Montreal 6
Stockholm 6
Catania 5
Columbus 5
Guangzhou 5
Manchester 5
Reggio Calabria 5
Seattle 5
Settingiano 5
Shanghai 5
The Dalles 5
Brescia 4
Charlotte 4
Chennai 4
Decollatura 4
Dhaka 4
Hanover 4
Jiaxing 4
Johannesburg 4
Mountain View 4
New Delhi 4
Pune 4
Redmond 4
Rio de Janeiro 4
Acquaviva delle Fonti 3
Ahmedabad 3
Berlin 3
Cape Town 3
Castrovillari 3
Denver 3
Frankfurt am Main 3
Jakarta 3
Manaus 3
Mexico City 3
Mileto 3
Nova Iguaçu 3
Nuremberg 3
Olomouc 3
Palermo 3
Paola 3
Phoenix 3
Porto Alegre 3
San Antonio 3
San Francisco 3
Sumaré 3
Tokyo 3
Treviso 3
Washington 3
6th of October City 2
Agrigento 2
Americana 2
Andover 2
Assago 2
Atlanta 2
Beirut 2
Bismarck 2
Biên Hòa 2
Bologna 2
Brasília 2
Brighton 2
Totale 1.588
Salva come PNG Salva come JPEG
Nome #
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 113
miR-22 suppresses DNA ligase III addiction in multiple myeloma 93
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 92
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 83
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 76
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 75
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 70
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 66
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 62
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 61
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 57
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 56
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 55
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 55
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 55
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 54
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 51
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 51
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 50
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 48
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 48
From single level analysis to multi-omics integrative approaches: A powerful strategy towards the precision oncology 48
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 47
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 46
Mir-221/222 are promising targets for innovative anticancer therapy 46
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity 45
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 45
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 45
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 44
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 44
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma 42
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 42
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 42
Distinctive role of the systemic inflammatory profile in non-small-cell lung cancer younger and elderly patients treated with a pd-1 immune checkpoint blockade: A real-world retrospective multi-institutional analysis 42
Mmrf-commpass data integration and analysis for identifying prognostic markers 41
Integration of DNA Microarray with Clinical and Genomic Data 41
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives 39
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity 39
Severe Hemodynamic Instability in a Young Pregnant Woman with Massive Pericardial Effusion and Pulmonary Embolism Secondary to Primary Mediastinal Non-Hodgkin's Lymphoma 38
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 38
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 37
Mirnas and lncrnas as novel therapeutic targets to improve cancer immunotherapy 37
Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes 36
Alternative non-homologous end-joining: Error-prone dna repair as cancer’s achilles’ heel 36
An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma 35
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity 34
From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology 32
null 31
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 29
Frontline therapy CLL without 17p del/p53 aberrations: systematic review and Bayesian network meta-analysis 27
The potential role of miRNAs in multiple myeloma therapy 27
Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma 27
MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches 27
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 26
Tools in Pharmacogenomics Biomarker Identification for Cancer Patients 26
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma 26
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 25
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma. 25
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts 23
UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma 22
The potential role of miRNAs in multiple myeloma therapy 22
Synthetic miR-22 impairs NHEJ repair sensistizing multiple myeloma cells to bortezomib-induced BRCAness 19
TERRA G-quadruplex stabilization behind the anti-multiple myeloma activity: Novel insights about resveratrol pleiotropic effects 18
Targeting oncogenic pri-miR-17-92 in multiple myeloma: molecular findings and therapeutic potential 18
Immunomodulatory activity of microRNAs: potential implications for multiple myeloma treatment. 17
CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy 8
Impact of COVID-19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase 7
Totale 2.882
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.471
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.471
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021107 0 0 0 0 12 9 11 10 25 20 15 5
2021/2022179 4 0 0 27 7 5 11 30 37 31 24 3
2022/2023541 95 29 32 21 64 38 6 39 76 54 68 19
2023/2024320 86 32 36 22 16 83 7 6 1 5 10 16
2024/2025886 88 26 29 37 59 132 39 45 70 10 130 221
2025/2026775 111 184 168 227 85 0 0 0 0 0 0 0
Totale 2.882